Drug intelligence / Profile preview

l-ornithine l-aspartate + silymarin (Atlina Lifesciences)

Development stage
Unknown
Lead developer
Atlina Life Sciences
Modality
Small Molecules
Administration
Oral
01

Overview

L-Corlina is a branded generic combination pharmaceutical product developed and marketed by Atlina Life Sciences, an Indian company focused on finished generic formulations. The drug is primarily indicated for the management of chronic liver diseases, including liver cirrhosis and hepatic encephalopathy. It contains two active components: l-ornithine l-aspartate (LOLA) and silymarin. LOLA is a stable salt of two amino acids that facilitates ammonia detoxification by providing substrates for the urea cycle in hepatocytes and glutamine synthesis in both the liver and brain. Silymarin, a flavonoid complex extracted from milk thistle (Silybum marianum), provides complementary hepatoprotective effects through its antioxidant activity, stabilization of hepatocyte membranes, and stimulation of ribosomal RNA synthesis, which aids in liver cell regeneration. As a branded generic, L-Corlina is marketed for retail and franchise distribution in the Indian pharmaceutical market.

Brand names
L-Corlina
Other names
L-CorlinaL-Ornithine L-Aspartate + SilymarinLOLA + Silymarin
02

Targets

OTC (Ornithine carbamoyltransferase)GLUL (Glutamine synthetase)ASS1 (Argininosuccinate synthase 1)CPS1 (Carbamoyl phosphate synthetase I)Pol I (RNA polymerase I)

Beyond the preview

Go deeper on l-ornithine l-aspartate + silymarin (Atlina Lifesciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-ornithine l-aspartate + silymarin (Atlina Lifesciences).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call